site stats

Host reduce polytech acs trial

WebSep 15, 2015 · Method/design: Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS) trial is a multicenter, randomized and open-label clinical study with a 2 × 2 factorial design, according to the type of stent (PtCr-EES … WebJul 16, 2024 · To date, three randomized trials have looked at de-escalation and shown promise—TOPIC, HOST-REDUCE-POLYTECH-ACS, and most recently TALOS-AMI—with the idea that the first month following PCI is the most vulnerable time for patients to report ischemic events.

Prasugrel-based de-escalation of dual antiplatelet therapy …

WebNov 15, 2024 · Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE … WebSep 8, 2024 · In die HOST-REDUCE-POLYTECH-ACS-Studie waren an 35 Kliniken in Südkorea insgesamt 2338 Patienten mit ACS aufgenommen worden, von denen 1170 der Gruppe mit Dosis-Deeskalation und 1168 der in üblicher Weise behandelten Gruppe zugeteilt waren. ... results from the HOST-REDUCE-POLYTECH-ACS trial, vorgestellt am 31.08.2024 beim … federal register waiver of overpayment https://beautydesignbyj.com

Harmonizing Optimal Strategy for Treatment of coronary artery …

WebOct 13, 2024 · Results From the HOST-REDUCE-POLYTECH-ACS Trial By Zuzana Motovska, MD, PhD Cardiocentre, Charles University and University Hospital Kralovske Vinohrady Prague, Czech Republic. Quick Takes. The goal of the trial was to assess the safety of reduced-dose prasugrel after 1 month of post-PCI treatment comparing ischemic events … WebJan 2, 2024 · The PROTECTED TAVR trial investigated the impact of cerebral embolic protection (CEP) during transcatheter aortic valve replacement (TAVR). 9 In the study population of 3000 patients, the incidence of stroke within 72 h after TAVR did not differ significantly between the CEP group and the control group. WebMar 9, 2024 · Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE … federal register va physician pay

Reduced Mortality With Antiplatelet Therapy Deescalation …

Category:Harmonizing Optimal Strategy for Treatment of coronary …

Tags:Host reduce polytech acs trial

Host reduce polytech acs trial

year in cardiovascular medicine 2024: the top 10 papers in ...

WebOct 17, 2024 · Presenting the HOST-Reduce-Polytech-ACS trial during a late-breaking clinical trial session at TCT Connect 2024, Hyo-Soo Kim, MD, PhD (Seoul National University Hospital, Korea), noted that the durable-polymer stent was not only noninferior to the biodegradable-polymer device, but also may have had some technical advantages. ... WebAug 27, 2024 · HOST-REDUCE-POLYTECH-ACS. Trial Description: Patients undergoing PCI for ACS were randomized in 2x2 factorial design to: a) either prasugrel 5 mg daily or …

Host reduce polytech acs trial

Did you know?

WebFeb 4, 2024 · Overall, 23,637 patients (62.6%) presented as ACS, and the follow-up duration ranged from 12 to 24 months. Five trials evaluated P2Y12 inhibitor monotherapy compared with DAPT, two trials evaluated the switch from a potent P2Y12 inhibitor to clopidogrel, and one trial evaluated switching the dose of prasugrel from 10 to 5 mg. WebOct 17, 2024 · The aim of the HOST-REDUCE-POLYTECH-ACS (Harmonizing Optima Strategy for Treatment of coronary artery diseases – Comparison of Reduction of prasugrel or …

WebACS patients were randomly assigned 1:1 to DP-DES or BP-DES in the HOST-REDUCE-POLYTECH-ACS trial. Complex PCI was defined as having at least 1 of the following features: ≥3 stents implanted, ≥3 lesions treated, total stent length ≥60 mm, bifurcation PCI with 2 stents, left main PCI, or heavy calcification. WebPrasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: Results from HOST-REDUCE-POLYTECH-ACS trial Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: Results from HOST-REDUCE-POLYTECH-ACS trial

WebOct 17, 2024 · NEW YORK - October 17, 2024 - A randomized clinical trial found that drug-eluting stents (DES) with durable polymers are non-inferior to DES with biodegradable … WebMay 14, 2024 · In HOST-REDUCE-POLYTECH-ACS, switching to prasugrel 5 mg daily after 1 month was superior to continuing with prasugrel 10 mg daily. References: Presented by Dr. Kiyuk Chang at the American College of Cardiology Virtual Annual Scientific Session (ACC 2024), May 16, 2024.

WebJan 28, 2024 · This was a post-hoc analysis of the HOST-REDUCE-POLYTECH-ACS (Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases—Comparison of Reduction of Prasugrel Dose or Polymer Technology in ACS Patients) randomized trial.

WebAug 24, 2024 · Durable polymer versus biodegradable polymer drug-eluting stents in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: a post hoc analysis of the HOST-REDUCE-POLYTECH-ACS trial Authors deducibile in ingleseWebOct 19, 2024 · A randomized clinical trial found that drug-eluting stents (DES) with durable polymers are non-inferior to DES with biodegradable polymers in patients with acute … deduce wordWebOct 17, 2024 · HOST-Reduce-Polytech-ACS. PCI. biodegradable polymer. Hyo-Soo Kim. Up Next. Presentation TCT 2024. Monitoring in Heart Failure: Promise and Reality. Presenter: Liviu Klein. October 17, 2024. More slides + Presentation TCT 2024. ... The HOST-Reduce-Polytech-ACS trial: Durable Polymer versus Biodegradable Polymer Drug-Eluting Stents … deduceyeWebTECHnology in ACS patients: HOST-REDUCE-POLYTECH-ACS trial . On behalf of the HOST-REDUCE-POLYTECH-ACS investigators. 2 . Table of Contents . 1. Investigators and Collaborators 2. Inclusion and Exclusion Criteria 3. Sample size calculation and Definition of Clinical outcomes 4. Supplementary Tables federal register wikipediaWebJul 18, 2014 · Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients … deducera synonymWebAug 29, 2024 · Highlighted text has been updated as of March 28, 2024. The HOST-REDUCE-POLYTECH-ACS trial showed that after 1 month of regular-dose DAPT, reduced … deduce xwordWebNov 18, 2024 · The HOST-REDUCE-POLYTECH-ACS (Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of Reduction of Prasugrel Dose … deduce the traitor\\u0027s identity